THOUSAND OAKS, Calif., September 7, 2006 -- Amgen (NASDAQ: AMGN) today announced the launch of the Aranesp® (darbepoetin alfa) prefilled SureClick TM autoinjector for patients with ...
THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...
This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
Patients with chemotherapy-induced anemia and anemia associated with chronic kidney disease (CKD) will now have access to Amgen's Aranesp, which is a prefilled autoinjector. The product will be ...
Sometimes no news is good news. That seems to be the case for Amgen Inc., which Thursday disclosed top-line Phase III data showing that Aranesp (darbepoetin alfa) did not raise safety concerns in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results